logo
logo

Acorn Biolabs raised $11 million CAD in Series A funding led by Merz Aesthetics to expand its regenerative medicine services

Jun 03, 2024•about 1 year ago

Amount Raised

$11 Million

Round Type

series a

TorontoBiotechnologyHealth Care

Investors

Lee Li HoldingsThe Leslie GroupMde InvestmentsTelus Global VenturesMerz Aesthetics

Description

Acorn Biolabs, founded in 2017, has announced approximately $11 million CAD ($8 million USD) in Series A funding to enhance its stem cell preservation services for personalized regenerative medicine. The funding round was led by Merz Aesthetics with support from Telus Global Ventures, MDE Investments, The Leslie Group, Lee Li Holdings, and several undisclosed physicians in the aesthetics, orthopedic, and longevity fields. Acorn plans to use the capital to expand its commercial footprint and develop cosmetic offerings.

Company Information

Company

Acorn Biolabs

Location

Toronto, Ontario, Canada

About

Toronto-based biotechnology startup Acorn Biolabs aims to provide clients with access to personalized regenerative medicine through preserving cells for future hair regrowth, skin rejuvenation, injury recovery, and disease treatment.

Related People

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech